Results 111 to 120 of about 34,133,693 (246)
Glucagon like peptide 1 receptor agonists: therapy for diabetes management
, 2017 Introduction: Glucagon-like peptide 1 agonists inhibit glucose-dependent glucagon secretion, decrease gastric emptying and appetite through neural mechanisms, contribute to glucose regulation and show reduction in glycated hemoglobin A.
Granados Vega, Elkyn Johan +1 more
core +1 more source
Glucagon-Like Peptide-1 Receptor Agonists: Beta-Cell Protection or Exhaustion?
, 2016 Glucagon-like peptide (GLP)-1 receptor agonists enhance insulin secretion and may improve pancreatic islet cell function. However, GLP-1 receptor (GLP-1R) agonist treatment may have more complex, and sometimes deleterious, effects on beta cells.
Verchere, C Bruce, van Raalte, Daniël H
core +1 more source
The Kaohsiung Journal of Medical Sciences, EarlyView.ABSTRACT Metabolic dysfunction‐associated steatotic liver disease (MASLD) has emerged as the most prevalent chronic liver disease worldwide, closely linked to the global rising incidence of obesity and metabolic syndrome. This review synthesizes current evidence on the pathogenesis, gut–liver axis, and multidisciplinary management of MASLD within the ...
Beom Kyung Kim
wiley +1 more source
Association of Glucagon‐Like Peptide—1 Receptor Analogues and Laryngeal Symptoms in Obese Adults
The Laryngoscope, EarlyView.Table 1 succinctly quantifies the time‑dependent association between GLP‑1RA/GIP therapy and laryngeal symptoms, demonstrating modest but statistically robust increases in outcomes such as cough and voice/resonance disorders by 6 months. It provides clinically actionable absolute risks, odds ratios, and hazard ratios that can directly inform counseling,
Priyanka Shah +4 more
wiley +1 more source
Glucagon like peptide 1 receptor agonists: a therapy for diabetes management
, 2018 Introduction: Glucagon-like peptide 1 agonists inhibit glucose-dependent glucagon secretion, decrease gastric emptying and appetite through neural mechanisms, contribute to glucose regulation and show reduction in glycated hemoglobin A.
Elkyn Johan Granados-Vega +3 more
core +1 more source
, 2018 Francesco Giorgino,1 Alfred Penfornis,2 Valeria Pechtner,3 Raffaella Gentilella,4 Antonella Corcos4 1Department of Emergency and Organ Transplantation, Section of Internal Medicine, Endocrinology, Andrology, and Metabolic Diseases, University of Bari ...
Corcos A +4 more
core
Movement Disorders Clinical Practice, EarlyView.Abstract Background Neurodegeneration with Brain Iron Accumulation (NBIA) is a heterogeneous group of heritable, mostly recessive, progressive neurodegenerative diseases characterized by iron deposition in the basal ganglia and brainstem. There are no solid global epidemiological data on prevalence and incidence of NBIA subtypes, but registry data and ...
Susanne A. Schneider +3 more
wiley +1 more source
Comparison of Effects of Glucagon-Like Peptide-1 Receptor Agonists Compared to Long-Acting Insulin, Added to Oral Anti-Diabetic Agents on Self-Management Behaviors, Anxiety, and Sleep Quality in Patients with Type 2 Diabetes [PDF]
Xiaoqing Song,1– 3,* Xueke Yang,1– 4,* Qinghua Liu,1– 4 Xuna Bian,1– 4 Lianlian Gao,1– 4 Jing Tao1– 4 1Department of Endocrinology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province ...
Yang X +5 more
core
High‐Fat Diet Exacerbates Neuropathology in a Transgenic Mouse Model of Multiple System Atrophy
Movement Disorders, EarlyView.Abstract Background Multiple system atrophy (MSA) is a rare and devastating neurodegenerative disorder. Accumulating clinical and preclinical evidence suggests that diabetes and insulin resistance may adversely influence MSA pathophysiology. Objective We investigated the potential association between diabetes, impaired glucose homeostasis, and MSA ...
Marie‐Laure Arotcarena +7 more
wiley +1 more source
, 2016 Heather L Gelhorn,1 Elizabeth D Bacci,2 Jiat Ling Poon,1 Kristina S Boye,3 Shuichi Suzuki,4 Steven M Babineaux3 1Outcomes Research, Evidera, Bethesda, MD, 2Evidera, Seattle, WA, 3Global Patient Outcomes and Real World Evidence, Eli Lilly and Company ...
Suzuki S +5 more
core